2.1
Lebrikizumab (Ebglyss, Almirall) is indicated for 'the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg who are candidates for systemic therapy'.
2 Information about lebrikizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for lebrikizumab.
Price
2.3
The list price for lebrikizumab is £2,271.26 per 2‑pack of 250 mg/2 ml solution for injection prefilled pens or syringes (excluding VAT; company submission, accessed April 2024).
2.4
The company has a commercial arrangement. This makes lebrikizumab available to the NHS with a discount. The size of the discount is commercial in confidence.